PRKCE and cancer: Our data encourage the consideration of TRPA1, the mesenchymal FGFR2c variant, and its hub signaling molecule PKCε as new molecular targets for precision oncology approaches to this recalcitrant cancer, which we hope will benefit an ever-larger group of patients.